CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
暂无分享,去创建一个
Alain Dupuy | Paul Ferrari | Christian Lange | Jochen Kruip | Anke Steinmetz | François Vallée | Christian Beil | Nicolas Baurin | Jochen Beninga | Cécile Capdevila | Carsten Corvey | Alexey Rak | Peter Wonerow | Vincent Mikol | Ercole Rao | A. Rak | F. Vallée | P. Ferrari | V. Mikol | N. Baurin | A. Dupuy | P. Wonerow | J. Beninga | Ercole Rao | Christian Beil | Christian Lange | J. Kruip | Carsten Corvey | A. Steinmetz | Cécile Capdevila
[1] R. Kontermann,et al. Dual targeting strategies with bispecific antibodies , 2012, mAbs.
[2] D. Haake,et al. The modification of human immunoglobulin binding to staphylococcal protein A using diethylpyrocarbonate. , 1982, Journal of immunology.
[3] Mieczyslaw Torchala,et al. The scoring of poses in protein-protein docking: current capabilities and future directions , 2013, BMC Bioinformatics.
[4] Z. Xiang,et al. On the role of the crystal environment in determining protein side-chain conformations. , 2002, Journal of molecular biology.
[5] Pamela J. Bjorkman,et al. Crystal structure of the complex of rat neonatal Fc receptor with Fc , 1994, Nature.
[6] Bruce Tidor,et al. Quantitative methods for developing Fc mutants with extended half-lives. , 2005, Biotechnology and bioengineering.
[7] E. Sasso,et al. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. , 1991, Journal of immunology.
[8] J. Marvin,et al. Recombinant approaches to IgG-like bispecific antibodies , 2005, Acta Pharmacologica Sinica.
[9] M. Kojima,et al. The role of interface framework residues in determining antibody VH/VL interaction strength and antigen‐binding affinity , 2006, The FEBS journal.
[10] U. Jacob,et al. Crystal structure of the soluble form of the human Fcγ‐receptor IIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution , 1999, The EMBO journal.
[11] R. Kontermann,et al. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.
[12] Chengbin Wu. Diabodies: molecular engineering and therapeutic applications. , 2009, Drug news & perspectives.
[13] Dongmei He,et al. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies , 2015, mAbs.
[14] J. Hess,et al. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. , 2009, Cancer research.
[15] Daniela Bumbaca,et al. Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics , 2012, The AAPS Journal.
[16] I. Pastan,et al. Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments , 1996, Nature Biotechnology.
[17] John D. Davis,et al. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. , 2016, Biopharmaceutics & drug disposition.
[18] Sahana Bose,et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.
[19] A. Plückthun,et al. Stability engineering of antibody single-chain Fv fragments. , 2001, Journal of molecular biology.
[20] M. Mack,et al. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[21] Shohei Koide,et al. Design of protein function leaps by directed domain interface evolution , 2008, Proceedings of the National Academy of Sciences.
[22] D. Roopenian,et al. Clinical Ramifications of the MHC Family Fc Receptor FcRn , 2010, Journal of Clinical Immunology.
[23] J. Deisenhofer. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.
[24] U. Jacob,et al. Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. , 2001, Journal of molecular biology.
[25] Hiroki Noguchi,et al. Computational design of a self-assembling symmetrical β-propeller protein , 2014, Proceedings of the National Academy of Sciences.
[26] Andrew Leaver-Fay,et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface , 2014, Nature Biotechnology.
[27] B. Carragher,et al. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen , 2013, mAbs.
[28] O. Ortmann,et al. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling , 2012, mAbs.
[29] E. Sasso,et al. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. , 1989, Journal of immunology.
[30] A. Urvoas,et al. Artificial proteins from combinatorial approaches. , 2012, Trends in biotechnology.
[31] M. Taussig,et al. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[32] W Wang,et al. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.
[33] Chan Hyuk Kim,et al. Bispecific small molecule–antibody conjugate targeting prostate cancer , 2013, Proceedings of the National Academy of Sciences.
[34] R. Landgraf,et al. Signaling through ERBB receptors: multiple layers of diversity and control. , 2006, Cellular signalling.
[35] Pei Zhou,et al. Suppression of conformational heterogeneity at a protein–protein interface , 2015, Proceedings of the National Academy of Sciences.
[36] Andrew C Doxey,et al. Modular evolution and the origins of symmetry: reconstruction of a three-fold symmetric globular protein. , 2012, Structure.
[37] Marc F Lensink,et al. Docking, scoring, and affinity prediction in CAPRI , 2013, Proteins.
[38] Yanay Ofran,et al. A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes , 2012, The Journal of Immunology.
[39] J. Chaparro-Riggers,et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity , 2015, mAbs.
[40] D. Röthlisberger,et al. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.
[41] Kenneth C. Anderson,et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.
[42] Diego Ellerman,et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.
[43] Nicholas Sawyer,et al. All repeats are not equal: a module-based approach to guide repeat protein design. , 2013, Journal of molecular biology.
[44] K. Garcia,et al. Molecular architecture of the αβ T cell receptor–CD3 complex , 2014, Proceedings of the National Academy of Sciences.
[45] R. Kontermann,et al. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A. , 2012, Protein engineering, design & selection : PEDS.
[46] C. Bokemeyer. Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites , 2010, Expert opinion on biological therapy.
[47] D. Burton,et al. Molecular selection of human antibodies with an unconventional bacterial B cell antigen. , 1993, Journal of immunology.
[48] Piet Gros,et al. Complement Is Activated by IgG Hexamers Assembled at the Cell Surface , 2014, Science.
[49] D. Dimitrov,et al. Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn , 2015, mAbs.
[50] M. Heiss,et al. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. , 2010, Future oncology.
[51] Herren Wu,et al. Insights into the molecular basis of a bispecific antibody's target selectivity , 2015, mAbs.
[52] A. Hemminki,et al. Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment , 2013, Journal of Translational Medicine.
[53] Brian Kuhlman,et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity , 2015, mAbs.
[54] S. Qiao,et al. Neonatal Fc Receptor: From Immunity to Therapeutics , 2010, Journal of Clinical Immunology.
[55] J. Reichert,et al. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA , 2012, mAbs.
[56] Hirotsugu Ogi,et al. Concentration dependence of IgG-protein A affinity studied by wireless-electrodeless QCM. , 2007, Biosensors & bioelectronics.
[57] R. Yeh,et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. , 2010, Blood.
[58] C. Klein,et al. Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain , 2013, PloS one.
[59] P. Carter,et al. Bispecific human IgG by design. , 2001, Journal of immunological methods.
[60] R. Majeti,et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells , 2015, mAbs.
[61] Jihong Wang,et al. Improving target cell specificity using a novel monovalent bispecific IgG design , 2015, mAbs.
[62] Misha V Golynskiy,et al. Rational design of FRET sensor proteins based on mutually exclusive domain interactions. , 2013, Biochemical Society transactions.
[63] G. A. Lazar,et al. Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[64] Inbal Sela-Culang,et al. The Structural Basis of Antibody-Antigen Recognition , 2013, Front. Immunol..
[65] M. Wittekind,et al. Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects , 2010, The Journal of Biological Chemistry.
[66] L. Regan,et al. NextGen protein design. , 2013, Biochemical Society transactions.
[67] J. Desjarlais,et al. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells , 2008, Molecular Cancer Therapeutics.
[68] Dan S. Tawfik,et al. Functional β-propeller lectins by tandem duplications of repetitive units. , 2011, Protein engineering, design & selection : PEDS.
[69] S. Kadono,et al. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant , 2013, mAbs.
[70] C. Jakob,et al. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule , 2013, mAbs.
[71] J. Huston,et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. , 2010, Protein engineering, design & selection : PEDS.
[72] F Bender,et al. Comparative study of IgG binding to proteins G and A: nonequilibrium kinetic and binding constant determination with the acoustic waveguide device. , 2003, Analytical chemistry.
[73] Zhiping Weng,et al. Docking unbound proteins using shape complementarity, desolvation, and electrostatics , 2002, Proteins.
[74] W. Sherman,et al. Probing the α‐Helical Structural Stability of Stapled p53 Peptides: Molecular Dynamics Simulations and Analysis , 2010, Chemical biology & drug design.
[75] Zhiping Weng,et al. Accelerating Protein Docking in ZDOCK Using an Advanced 3D Convolution Library , 2011, PloS one.
[76] Kunihiro Hattori,et al. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. , 2014, Molecular immunology.
[77] Guy Georges,et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.
[78] G. Winter,et al. Retargeting serum immunoglobulin with bispecific diabodies , 1997, Nature Biotechnology.
[79] Gili Bisker,et al. Mechanism of immobilized protein A binding to immunoglobulin G on nanosensor array surfaces. , 2015, Analytical Chemistry.
[80] P. Moore,et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates , 2015, Science Translational Medicine.
[81] John Kelly,et al. Improving biophysical properties of a bispecific antibody scaffold to aid developability , 2013, mAbs.
[82] K. Avery,et al. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies , 2013, Proceedings of the National Academy of Sciences.
[83] B. Honig,et al. A hierarchical approach to all‐atom protein loop prediction , 2004, Proteins.
[84] Michael Blaber,et al. Designing proteins from simple motifs: opportunities in Top-Down Symmetric Deconstruction. , 2012, Current opinion in structural biology.
[85] P. Bjorkman,et al. Fc receptors and their interactions with immunoglobulins. , 1996, Annual review of cell and developmental biology.
[86] R. Raag,et al. Single‐chain Fvs , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] Diego Ellerman,et al. Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies , 2015, Science Translational Medicine.
[88] Robert Huber,et al. The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex , 2000, Nature.
[89] B. Bast,et al. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19) , 1992 .
[90] C. Jakob,et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design , 2011, mAbs.
[91] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[92] Yan Feng,et al. Alteration of substrate specificities of thermophilic α/β hydrolases through domain swapping and domain interface optimization. , 2012, Acta biochimica et biophysica Sinica.
[93] D. Driver,et al. FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys , 2012, Drug Metabolism and Disposition.